



Rebiotix Media Contact:
Jason Rando
Tiberend Strategic Advisors
212-375-2665
jrando@tiberend.com

Rebiotix Participating in Multiple Events During J.P. Morgan 36th Annual Healthcare Conference 2018 Week

Rebiotix's president & CEO, Lee Jones, to participate in BDO's Panel Trifecta at the Annual JP Morgan Healthcare Conference

Rebiotix to present at Biotech Showcase™ 2018 and China Showcase 2018

ROSEVILLE, MN – January 4, 2018 – [Rebiotix Inc.](#), a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat debilitating diseases, today announced that it will participate in several events during the [J.P. Morgan 36th Annual Healthcare Conference 2018](#) week (January 8-11, 2018).

[Lee Jones](#), Rebiotix's co-founder, president and CEO, will participate in BDO's Panel Trifecta at the Annual JP Morgan Healthcare Conference being held Wednesday, January 10, 2018, at the Four Seasons Hotel in San Francisco. Ms. Jones will offer her perspective on a panel entitled, "Adjusting to Disruption: The 'New Normal' in Healthcare?" The panel will look at how new products are paving the way for startups and traditional providers to better meet the needs of today's empowered consumers, and what other areas of healthcare are ripe for disruption.

[Greg Fluet](#), Rebiotix's Chief Business Officer, will present at Biotech Showcase™ 2018 being held January 8-10, 2018, at the Hilton Hotel in San Francisco, California, and at the China Showcase on Sunday, January 7, 2018, at the Parc 55 San Francisco. Mr. Fluet will discuss the company's key milestones and accomplishments, growth strategy, pioneering [Microbiota Restoration Therapy™ \(MRT™\) platform](#), and rapidly advancing drug development pipeline, highlighted by [RBX2660](#) and [RBX7455](#). RBX2660 is currently being evaluated in an international [Phase 3 clinical trial for the prevention of recurrent *Clostridium difficile* \(C. diff\) infection](#), while RBX7455, a lyophilized, non-frozen, oral capsule formulation, is the subject of a Phase 1 clinical study for the prevention of recurrent C. diff infection.



Details of Rebiotix's events are as follows:

Event: **China Showcase 2018**
Date: Sunday, January 7, 2018
Time: 5:15 p.m. (Pacific Time)
Location: Parc 55 San Francisco, Cyril Magnin I Ballroom; San Francisco, CA

Event: **Biotech Showcase™ 2018**
Date: Tuesday, January 9, 2018
Time: 11:45 a.m. (Pacific Time)
Location: Hilton Hotel, Franciscan B Ballroom; San Francisco, CA

Event: **BDO's Panel Trifecta at the Annual JP Morgan Healthcare Conference**
Panel: *Adjusting to Disruption: The 'New Normal' in Healthcare?*
Date: Wednesday, January 10, 2018
Time: 10:30 a.m. (Pacific Time)
Location: Four Seasons Hotel, Yerba Buena Room

About Rebiotix Inc.

Rebiotix Inc. is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent *Clostridium difficile* (*C. diff*) infection. RBX2660 has been granted [Fast Track status](#), Orphan Drug and [Breakthrough Therapy designation from the FDA](#) for its potential to prevent recurrent *C. diff* infection. Rebiotix's clinical pipeline also features RBX7455, a lyophilized non-frozen, oral capsule formulation, which is currently the subject of an [investigator-sponsored Phase 1 trial for the prevention of recurrent *C. diff* infection](#). In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy™ (MRT™) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient's intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.